Biotech Paradox: Aptevo’s Groundbreaking Cancer Data Fails to Halt Stock Collapse

Aptevo Therapeutics continues to experience one of the most dramatic stock market declines this year, with shares plummeting nearly 99% over the past twelve months. This freefall persists despite the biotechnology firm reporting exceptional clinical trial results that would typically generate significant investor enthusiasm.

The company’s drug candidate mipletamig demonstrated remarkable efficacy in the RAINIER study for acute myeloid leukemia treatment, achieving a complete 100% remission rate among participants. Such breakthrough data would normally propel a biotech stock upward, yet Aptevo shares continue their relentless descent.

Recent trading saw the equity sink to $1.43 per share, extending a downward trajectory that shows no signs of abating. The performance metrics paint a stark picture:
* Weekly decline: -4.67%
* Monthly decrease: -10.06%
*... Read more...